Bristol-Myers Squ…
USUSDBristol-Myers Squibb Company (XETRA:BRM) — Drug Manufacturers - General. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 6. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het Bedrijf
- Website
- bms.com
- Beleggersrelaties
- bms.com/investors.html
- Sector
- Healthcare · Drug Manufacturers - General
- Hoofdkantoor
- PRINCETON, United States
- CEO
- Christopher S. Boerner
- Werknemers
- 32 500
- Opgericht
- 1989
- Uitstaande Aandelen
- 2.04 mld. per 2026-07-22
- Free Float
- 2.04 mld.
- Marktkapitalisatie
- 128.41 mld. USD
- Insiders
- 0.1%
- Institutionele Beleggers
- 84.87%
- Branche (SIC)
- Pharmaceutical Preparations
- Rechtsvorm
- XTIQ
- ISIN
- US1101221083
- LEI
- HLYYNH7UQUORYSJQCN42
- P/E
- 13.8
- Uitkeringsratio
- 54.9%
- FCF
- 11.4 mld. USD
- Uitkering / FCF
- 45%
- Schuld
- 43.9 mld. USD3.1 jr FCF
- Dividendreeks
- 54 jr
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Beurzen en Tickers
| Beurs | Ticker | Valuta | Prijs | Type |
|---|---|---|---|---|
| US USA Stocks | BMY primair | USD | 57.58 -2.60% | gewone aandelen |
| LSE London Stock Exchange | 0R1F IOB | GBP | — | gewone aandelen |
| MI Borsa Italiana (Milan) | 1BMY secundair | EUR | 53.13 +0.28% | gewone aandelen |
| MX Mexican Stock Exchange | BMY secundair | MXN | 1 047 -3.81% | gewone aandelen |
| VI Vienna Stock Exchange | BMYS secundair | EUR | 52.98 +0.34% | gewone aandelen |
| XETRA Xetra | BRM secundair | EUR | 53.04 +0.89% | gewone aandelen |
Dividenden
Bristol-Myers Squibb Company (BMYS) betaalt elk kwartaal dividend uit. Per jaar (12 maanden tot en met de laatst aangekondigde betaling): 0.562 EUR per aandeel (betalingen: 1). Dat is ongeveer 1.06% van de huidige aandelenkoers. Op basis van de betalingsgeschiedenis wordt de volgende ex-dividenddatum verwacht rond 01.01.2027. Ononderbroken dividendgeschiedenis: 54 jaar.
| Ex-Datum | Uitbetaling | Bedrag | % | Type | Ticker |
|---|---|---|---|---|---|
| 2026-10-02 | — | 0.5620 EUR | 1.0/4.0 % | — | VI:BMYS |
| 2026-07-02 | — | 0.5540 EUR | 1.1/4.4 % | per kwartaal | XETRA:BRM |
| 2026-04-02 | — | 0.5540 EUR | 1.0/4.2 % | per kwartaal | XETRA:BRM |
| 2026-01-02 | — | 0.5540 EUR | 1.2/4.8 % | per kwartaal | XETRA:BRM |
| 2025-10-03 | — | 0.5452 EUR | 1.4/5.5 % | per kwartaal | XETRA:BRM |
| 2025-07-03 | — | 0.5452 EUR | 1.3/5.3 % | per kwartaal | XETRA:BRM |
| 2025-04-04 | — | 0.5452 EUR | 1.0/4.0 % | per kwartaal | XETRA:BRM |
| 2025-01-03 | — | 0.5452 EUR | 1.0/3.8 % | per kwartaal | XETRA:BRM |
| 2024-10-04 | — | 0.5276 EUR | 1.1/4.3 % | per kwartaal | XETRA:BRM |
| 2024-07-05 | — | 0.5276 EUR | 1.4/5.6 % | per kwartaal | XETRA:BRM |
| 2024-04-04 | — | 0.5276 EUR | 1.1/4.3 % | per kwartaal | XETRA:BRM |
| 2024-01-04 | — | 0.5276 EUR | 1.1/4.2 % | per kwartaal | XETRA:BRM |
| 2023-10-05 | — | 0.5013 EUR | 0.9/3.7 % | per kwartaal | XETRA:BRM |
| 2023-07-06 | — | 0.5013 EUR | 0.8/3.3 % | per kwartaal | XETRA:BRM |
| 2023-04-06 | — | 0.5013 EUR | 0.8/3.0 % | per kwartaal | XETRA:BRM |
| 2023-01-05 | — | 0.5013 EUR | 0.7/2.8 % | per kwartaal | XETRA:BRM |
| 2022-10-06 | — | 0.4749 EUR | 0.7/2.6 % | per kwartaal | XETRA:BRM |
| 2022-06-30 | — | 0.4749 EUR | 0.6/1.9 % | per kwartaal | XETRA:BRM |
| 2022-03-31 | — | 0.4749 EUR | 0.7/1.4 % | per kwartaal | XETRA:BRM |
| 2022-01-06 | — | 0.4749 EUR | 0.9/0.9 % | per kwartaal | XETRA:BRM |
Nieuws Deze Week
Persberichten van de investeerderswebsite van het bedrijf, dagelijks bijgewerkt. Links leiden naar de website van het bedrijf. De koppen zijn in de oorspronkelijke taal, zoals op de bedrijfswebsite.
Grootste Aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| Blackrock Inc. | 8.83% | 180.38 mln. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 133.34 mln. | 2026-06-30 |
| State Street Corporation | 5.01% | 102.41 mln. | 2026-06-30 |
| JPMORGAN CHASE & CO | 3.51% | 71.71 mln. | 2026-06-30 |
| Charles Schwab Investmen… | 3.31% | 67.6 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 64.83 mln. | 2026-06-30 |
| Geode Capital Management… | 2.76% | 56.44 mln. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 52.92 mln. | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 2.38% | 48.64 mln. | 2026-05-31 |
| Vanguard Portfolio Manag… | 2.29% | 46.87 mln. | 2026-06-30 |
| NORGES BANK | 1.8% | 36.87 mln. | 2026-06-30 |
| Bank of America Corporat… | 1.67% | 34.05 mln. | 2026-06-30 |
| Price (T.Rowe) Associate… | 1.55% | 31.71 mln. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 27.55 mln. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 26.41 mln. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 24.96 mln. | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 19.44 mln. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 14.68 mln. | 2026-08-31 |
| VANGUARD CHESTER FUNDS-V… | 0.7% | 14.29 mln. | 2026-06-30 |
| VANGUARD INSTITUTIONAL I… | 0.54% | 11.09 mln. | 2026-06-30 |
| LEUNG SANDRA (General Co… | ≈0.02% | 465 374 | 2025-03-10 |
| ELKINS DAVID VINCENT (Ch… | ≈0.01% | 159 542 | 2026-04-01 |
| BOERNER CHRISTOPHER S (C… | ≈0.01% | 146 890 | 2026-03-10 |
| HIRAWAT SAMIT (Officer) | ≈0% | 83 513 | 2025-04-25 |
| HALLER JULIA A (Director… | ≈0% | 34 079 | 2026-06-15 |
| MEYERS GREGORY SCOTT (Ch… | ≈0% | 30 361 | 2026-03-10 |
| LENKOWSKY ADAM (Officer) | ≈0% | 28 677 | 2026-05-01 |
| SHANAHAN KARIN (Officer) | ≈0% | 27 345 | 2026-04-01 |
| PLENGE ROBERT M (Officer… | ≈0% | 24 754 | 2026-03-10 |
| MASSACESI CRISTIAN (Offi… | ≈0% | 18 748 | 2026-09-09 |
